Vistagen Therapeutics (VTGN) Total Non-Current Liabilities (2011 - 2023)

Vistagen Therapeutics has reported Total Non-Current Liabilities for 11 years, with the latest figure at $7.8 million in Q4 2023.

• Quarterly Total Non-Current Liabilities rose 63.96% year-over-year to $7.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $7.8 million (up 63.96% YoY) and the FY2023 annual result came in at $4.4 million, up 6.7% from the prior year.
• Total Non-Current Liabilities advanced to $7.8 million in Q4 2023 per VTGN's latest filing, from $3.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $12.7 million in Q3 2020 and troughed at $3.6 million in Q3 2023.
• A 5-year average of $7.5 million and a median of $7.9 million in 2019 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2019 and 2022: Total Non-Current Liabilities surged 153.39% in 2019, then sank 68.83% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $8.5 million in 2019, then soared by 47.01% to $12.5 million in 2020, then sank by 66.85% to $4.1 million in 2021, then increased by 14.73% to $4.7 million in 2022, then soared by 63.96% to $7.8 million in 2023.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $7.8 million, $3.6 million, and $4.1 million for Q4 2023, Q3 2023, and Q2 2023 respectively.